Cadila Healthcare and Zydus Pharmaceuticals today said they have entered into a settlement agreement with Depomed Inc pertaining to patent infringement.
The case is related to Depomed's neuropathic pain relieving drug 'Gralise'.
Cadila Healthcare and Zydus Pharmaceuticals today announced in a joint statement that "they have entered into a settlement agreement with Depomed" regarding the patent infringement litigation related to Gralise 300 mg and 600 mg tablets.
Also Read
The settlement will allow Cadila and Zydus to begin sell of generic versions of Gralise on January 1, 2024, or earlier under certain circumstances, the company said.
Other terms of the settlement were not disclosed.
"The agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey," the statement said.
